Detalhe da pesquisa
1.
IRF2BPL Is Associated with Neurological Phenotypes.
Am J Hum Genet;
103(2): 245-260, 2018 08 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30057031
2.
Evaluation of non-reducing end pathologic glycosaminoglycan detection method for monitoring therapeutic response to enzyme replacement therapy in human mucopolysaccharidosis I.
Mol Genet Metab;
129(2): 91-97, 2020 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31630958
3.
IRF2BPL Is Associated with Neurological Phenotypes.
Am J Hum Genet;
103(3): 456, 2018 09 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30193138
4.
Combining angiotensin receptor blockade and enzyme replacement therapy for vascular disease in mucopolysaccharidosis type I.
Mol Genet Metab Rep;
38: 101036, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38173710
5.
Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.
Mol Genet Metab;
106(1): 68-72, 2012 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22402327
6.
A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I.
Mol Ther Methods Clin Dev;
8: 42-51, 2018 Mar 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29159202
7.
Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I.
PLoS One;
11(3): e0150850, 2016.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26986213